A Phase 3 interventional study of Ranibizumab in Macular Degeneration, sponsored by Xbrane Biopharma AB. Completed at 102 sites in 15 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.
Sponsored by Xbrane Biopharma AB · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 13th largest by enrollment of the 124 interventional ones that give a count, is one of 2 that started in 2019, is one of 31 in phase 3, and was the 111th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 582 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Xbrane Biopharma AB as lead sponsor.
Xbrane Biopharma AB has 1 study filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).
This is a phase III multicenter, double-masked, randomized, parallel group study in subjects with wAMD. Approximately 580 subjects will be enrolled and randomized in a 1:1 ratio to receive either Lucentis® or the investigational product, Xlucane in the study eye once every 4 weeks for 52 weeks. The study eye will be defined as the eye meeting the enrollment criteria. The assigned study drug will be administered as an ophthalmic intravitreal (IVT) injection. A subgroup of 60 subjects at a select number of participating sites will be sequentially asked to participate in an evaluation of PK.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Newly diagnosed, active subfoveal Choroidal Neovascularization (CNV) lesion secondary to age-related macular degeneration (AMD) in the study eye. Note: Active CNV indicates the presence of leakage as evidenced by Fluorescein Angiography (FA) and intra- or subretinal fluid as evidenced by Optical Coherence Tomography (OCT) which must be confirmed by the central reading center during Screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
Biological: Ranibizumab
Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
Biological: Ranibizumab
Intravitreal injection
Change in Best Corrected Visual Acuity (BCVA)
Change(s) in BCVA letters at Week 8 compared to baseline using the ETDRS protocol
Time frame: Baseline and Week 8
Change From Baseline in the Total Size of Choroidal Neovascular Leakage Area in the Study Eye
Change in the total size of choroidal neovascular leakage area in the study eye week 52 compared to baseline measured by Fluorescein Angiography
Time frame: Baseline and Week 52
Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye
Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye Measured by Fluorescein Angiography
Time frame: Baseline and week 52
Central Foveal Thickness in the Study Eye
Central Foveal Thickness in the Study Eye Measured by Optical Coherence Tomography
Time frame: Baseline to week 52
Percentage of Subjects With Loss of <15 BCVA Letters
Percentage of Subjects With Loss of \<15 BCVA Letters Compared to Baseline in the Study Eye
Time frame: Baseline to week 52
Percentage of Subjects With Gain of ≥15 BCVA Letters
Percentage of Subjects With Gain of ≥15 BCVA Letters Compared to Baseline in the Study Eye
Time frame: Baseline to week 52
Subretinal Fluid in the Study Eye
Change from Baseline in the Amount of Subretinal Fluid in the Study Eye Measured by OCT
Time frame: Baseline to week 52
Width of Retinal Pigment Epithelium Detachments in the Study Eye
Change from Baseline in the Width of Retinal Pigment Epithelium Detachments in the Study Eye Measured by OCT
Time frame: Baseline to Week 52
Pharmacokinetic Plasma Ranibizumab Concentrations
Pharmacokinetic Plasma Ranibizumab Concentrations (sub-study)
Time frame: Day 1 to week 20
Height of Retinal Pigment Epithelium Detachments
Change from Baseline in the Height of Retinal Pigment Epithelium Detachments in the Study Eye Measured by OCT
Time frame: Baseline to Week 52
| Milestone | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Started | 292 | 290 |
| Completed | 245 | 241 |
| Not completed | 47 | 49 |
Change(s) in BCVA letters at Week 8 compared to baseline using the ETDRS protocol
| Letters | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Change in Best Corrected Visual Acuity (BCVA) | 4.57 (3.54 to 5.61) | 6.37 (5.31 to 7.42) |
Change in the total size of choroidal neovascular leakage area in the study eye week 52 compared to baseline measured by Fluorescein Angiography
| mm2 | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Change From Baseline in the Total Size of Choroidal Neovascular Leakage Area in the Study Eye | -4.09 (-4.66 to -3.52) | -3.71 (-4.28 to -3.14) |
Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye Measured by Fluorescein Angiography
| mm2 | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Change From Baseline in the Total Size of Choroidal Neovascularisation in the Study Eye | -1.62 (-2.19 to -1.05) | -1.11 (-1.68 to -0.54) |
Central Foveal Thickness in the Study Eye Measured by Optical Coherence Tomography
| um | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Central Foveal Thickness in the Study Eye | -117.44 (-125.33 to 109.55) | -115.14 (-123.14 to -107.14) |
Percentage of Subjects With Loss of \<15 BCVA Letters Compared to Baseline in the Study Eye
| percentage of responders | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Missing at random (MAR) | 94.8 | 96.0 |
| Missing completely at random (MCAR) | 94.9 | 96.1 |
| Missing not at random (MNAR) | 94.8 | 96.1 |
| Composite (Missing and non-evaluable data are classed as no response) | 68.8 | 67.6 |
Percentage of Subjects With Gain of ≥15 BCVA Letters Compared to Baseline in the Study Eye
| percentage of responders | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Missing at random (MAR) | 23.6 | 29.7 |
| Missing completely at random (MCAR) | 23.2 | 28.8 |
| Missing not at random (MNAR) | 23.6 | 30.4 |
| Composite (Missing and non-evaluable data are classed as no response) | 17.1 | 21.4 |
Change from Baseline in the Amount of Subretinal Fluid in the Study Eye Measured by OCT
| um | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Subretinal Fluid in the Study Eye | -34.88 (-39.07 to -30.69) | -32.93 (-37.21 to -28.65) |
Change from Baseline in the Width of Retinal Pigment Epithelium Detachments in the Study Eye Measured by OCT
| um | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Width of Retinal Pigment Epithelium Detachments in the Study Eye | -161.39 (-387.16 to -135.62) | -256.33 (-384.56 to -128.10) |
Pharmacokinetic Plasma Ranibizumab Concentrations (sub-study)
| pg/mL | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Day 1 | 2230 ± 1429 | 2190 ± 1336 |
| Week 20 | 2450 ± 1384 | 2150 ± 1233 |
Change from Baseline in the Height of Retinal Pigment Epithelium Detachments in the Study Eye Measured by OCT
| um | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| Height of Retinal Pigment Epithelium Detachments | -81.49 (-96.33 to -66.66) | -73.15 (-88.35 to -57.95) |
Collected over From the time the participant signed the written informed consent to 28 days [± 5 days] of receiving last dose of study drug, up to 53 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Xlucane (Proposed Ranibizumab Biosimilar) | 8/292 (2.7%) | 33/292 (11.3%) | 25/292 (8.6%) |
| Lucentis (Ranibizumab) | 3/290 (1%) | 35/290 (12.1%) | 33/290 (11.4%) |
| Event | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| COVID-19Infections and infestations | 5/292 | 1/290 |
| Myocardial infractionCardiac disorders | 0/292 | 3/290 |
| Urinary tract infectionInfections and infestations | 3/292 | 0/290 |
| Artrial fibrilationCardiac disorders | 3/292 | 2/290 |
| Humerus fractureInjury, poisoning and procedural complications | 3/292 | 0/290 |
| Inguinal herniaGastrointestinal disorders | 0/292 | 2/290 |
| Pancreatitis acuteGastrointestinal disorders | 0/292 | 2/290 |
| Transient ischaemic attackNervous system disorders | 0/292 | 2/290 |
| Retinal pigment epithelial tearEye disorders | 2/292 | 1/290 |
| PneumoniaInfections and infestations | 2/292 | 1/290 |
| Event | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) |
|---|---|---|
| HypertensionVascular disorders | 10/292 | 17/290 |
| Conjunctival HaemorrhageEye disorders | 15/292 | 16/290 |
All 292 subjects in the Xlucane group, and 289 out of the 290 subjects in the Lucentis group were dosed with study drug. 1 subject in the Lucentis group withdrew consent after randomization, and was never treated, therefore was never exposed to study drug.
| Age, Categorical(Participants) | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 34 | 32 | 66 |
| >=65 years | 258 | 258 | 516 |
| Age, Continuous(Years) | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) | Total |
|---|---|---|---|
| Mean | 74.5 ± 8.68 | 73.8 ± 8.25 | 74.1 ± 8.47 |
| Sex: Female, Male(Participants) | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) | Total |
|---|---|---|---|
| Female | 168 | 157 | 325 |
| Male | 124 | 133 | 257 |
| Race (NIH/OMB)(Participants) | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 44 | 42 | 86 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 248 | 248 | 496 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Best Corrected Visual Acuity(Letters) | Xlucane (Proposed Ranibizumab Biosimilar) | Lucentis (Ranibizumab) | Total |
|---|---|---|---|
| Mean | 61.7 ± 8.11 | 61.5 ± 8.20 | 61.6 ± 8.15 |
Showing the first 100 of 102 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in May 2021, 24 months.
Results were first posted in Nov 2023, 2 years 6 months after primary completion.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 24 months is close to that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab